Cargando…

SYST-24 PROPOFOL EXERTS ANTI-TUMOR EFFECTS IN GLIOMA AND THE TUMOR MICROENVIRONMENT VIA NON-CODING RNAS AND SECRETED EXOSOMES

BACKGROUND: Glioblastoma (GBM), is the most common primary brain tumor. GBM contains a small subpopulation of glioma stem cells (GSCs) that are implicated in tumor recurrence and treatment resistance and therefore represent important therapeutic targets. Recent clinical studies suggest propofol impa...

Descripción completa

Detalles Bibliográficos
Autores principales: Penning, Donald, Cazacu, Simona, Nizar, Raphael, Xiang, Cunli, Goldstein, Hodaya, Krasner, Matan, Barbiro-Michaely, Efrat, Gerber, Doron, Kazimirsky, Gila, Rogers, Lisa, Brown, Stephan, Brodie, Chaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402310/
http://dx.doi.org/10.1093/noajnl/vdad070.126
_version_ 1785084846465351680
author Penning, Donald
Cazacu, Simona
Nizar, Raphael
Xiang, Cunli
Goldstein, Hodaya
Krasner, Matan
Barbiro-Michaely, Efrat
Gerber, Doron
Kazimirsky, Gila
Rogers, Lisa
Brown, Stephan
Brodie, Chaya
author_facet Penning, Donald
Cazacu, Simona
Nizar, Raphael
Xiang, Cunli
Goldstein, Hodaya
Krasner, Matan
Barbiro-Michaely, Efrat
Gerber, Doron
Kazimirsky, Gila
Rogers, Lisa
Brown, Stephan
Brodie, Chaya
author_sort Penning, Donald
collection PubMed
description BACKGROUND: Glioblastoma (GBM), is the most common primary brain tumor. GBM contains a small subpopulation of glioma stem cells (GSCs) that are implicated in tumor recurrence and treatment resistance and therefore represent important therapeutic targets. Recent clinical studies suggest propofol impacts subsequent tumor response to treatments and patient prognosis. The effects of propofol on patient derived GSCs alone and in combination with radiation and temozolomide, (TMZ) have not been reported. Objectives: The molecular mechanisms underlying propofol’s anti-tumor effects on GSCs and its effect on cellular communication with microglia was studied. Using GSC spheroids, differentiated glioma and tumor cells on a microfluid chip, effects of propofol alone and together with radiation and TMZ on the self-renewal and stemness of GSCs, their mesenchymal transit and the proliferation and apoptosis of differentiated glioma cells was analyzed. Using transwell plates, the effects of propofol on the cross-talk of GSCs with human microglia cells was examined. RESULTS: Propofol exerted a dose-dependent inhibitory effect on the self-renewal, expression of mesenchymal markers and migration of GSCs and sensitized them to both temozolomide (TMZ) and radiation. At higher concentrations propofol induced a large degree of cell death as demonstrated using microfluid chip. Propofol increased the expression of the lncRNA BDNF-AS, which acts as a tumor suppressor in GBM and silencing of this lncRNA partially abrogated propofol’s anti-tumor effects. Propofol also inhibited the pro-tumorigenic GSC-microglia cross talk via extracellular vesicles (EVs) and delivery of BDNF-AS. CONCLUSIONS: Propofol exerted anti-tumor effects on GSCs and differentiated glioma cells by inhibiting cell renewal, proliferation, and mesenchymal transition and by inducing cell death at higher concentration. Propofol also sensitized GSCs to radiation and TMZ. Propofol, which is widely used in GBM surgeries, should be further explored as a potential repurposed drug during resection and an effective adjunct to radiation and TMZ.
format Online
Article
Text
id pubmed-10402310
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104023102023-08-05 SYST-24 PROPOFOL EXERTS ANTI-TUMOR EFFECTS IN GLIOMA AND THE TUMOR MICROENVIRONMENT VIA NON-CODING RNAS AND SECRETED EXOSOMES Penning, Donald Cazacu, Simona Nizar, Raphael Xiang, Cunli Goldstein, Hodaya Krasner, Matan Barbiro-Michaely, Efrat Gerber, Doron Kazimirsky, Gila Rogers, Lisa Brown, Stephan Brodie, Chaya Neurooncol Adv Final Category: Systemic Therapeutics BACKGROUND: Glioblastoma (GBM), is the most common primary brain tumor. GBM contains a small subpopulation of glioma stem cells (GSCs) that are implicated in tumor recurrence and treatment resistance and therefore represent important therapeutic targets. Recent clinical studies suggest propofol impacts subsequent tumor response to treatments and patient prognosis. The effects of propofol on patient derived GSCs alone and in combination with radiation and temozolomide, (TMZ) have not been reported. Objectives: The molecular mechanisms underlying propofol’s anti-tumor effects on GSCs and its effect on cellular communication with microglia was studied. Using GSC spheroids, differentiated glioma and tumor cells on a microfluid chip, effects of propofol alone and together with radiation and TMZ on the self-renewal and stemness of GSCs, their mesenchymal transit and the proliferation and apoptosis of differentiated glioma cells was analyzed. Using transwell plates, the effects of propofol on the cross-talk of GSCs with human microglia cells was examined. RESULTS: Propofol exerted a dose-dependent inhibitory effect on the self-renewal, expression of mesenchymal markers and migration of GSCs and sensitized them to both temozolomide (TMZ) and radiation. At higher concentrations propofol induced a large degree of cell death as demonstrated using microfluid chip. Propofol increased the expression of the lncRNA BDNF-AS, which acts as a tumor suppressor in GBM and silencing of this lncRNA partially abrogated propofol’s anti-tumor effects. Propofol also inhibited the pro-tumorigenic GSC-microglia cross talk via extracellular vesicles (EVs) and delivery of BDNF-AS. CONCLUSIONS: Propofol exerted anti-tumor effects on GSCs and differentiated glioma cells by inhibiting cell renewal, proliferation, and mesenchymal transition and by inducing cell death at higher concentration. Propofol also sensitized GSCs to radiation and TMZ. Propofol, which is widely used in GBM surgeries, should be further explored as a potential repurposed drug during resection and an effective adjunct to radiation and TMZ. Oxford University Press 2023-08-04 /pmc/articles/PMC10402310/ http://dx.doi.org/10.1093/noajnl/vdad070.126 Text en © The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Final Category: Systemic Therapeutics
Penning, Donald
Cazacu, Simona
Nizar, Raphael
Xiang, Cunli
Goldstein, Hodaya
Krasner, Matan
Barbiro-Michaely, Efrat
Gerber, Doron
Kazimirsky, Gila
Rogers, Lisa
Brown, Stephan
Brodie, Chaya
SYST-24 PROPOFOL EXERTS ANTI-TUMOR EFFECTS IN GLIOMA AND THE TUMOR MICROENVIRONMENT VIA NON-CODING RNAS AND SECRETED EXOSOMES
title SYST-24 PROPOFOL EXERTS ANTI-TUMOR EFFECTS IN GLIOMA AND THE TUMOR MICROENVIRONMENT VIA NON-CODING RNAS AND SECRETED EXOSOMES
title_full SYST-24 PROPOFOL EXERTS ANTI-TUMOR EFFECTS IN GLIOMA AND THE TUMOR MICROENVIRONMENT VIA NON-CODING RNAS AND SECRETED EXOSOMES
title_fullStr SYST-24 PROPOFOL EXERTS ANTI-TUMOR EFFECTS IN GLIOMA AND THE TUMOR MICROENVIRONMENT VIA NON-CODING RNAS AND SECRETED EXOSOMES
title_full_unstemmed SYST-24 PROPOFOL EXERTS ANTI-TUMOR EFFECTS IN GLIOMA AND THE TUMOR MICROENVIRONMENT VIA NON-CODING RNAS AND SECRETED EXOSOMES
title_short SYST-24 PROPOFOL EXERTS ANTI-TUMOR EFFECTS IN GLIOMA AND THE TUMOR MICROENVIRONMENT VIA NON-CODING RNAS AND SECRETED EXOSOMES
title_sort syst-24 propofol exerts anti-tumor effects in glioma and the tumor microenvironment via non-coding rnas and secreted exosomes
topic Final Category: Systemic Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402310/
http://dx.doi.org/10.1093/noajnl/vdad070.126
work_keys_str_mv AT penningdonald syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT cazacusimona syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT nizarraphael syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT xiangcunli syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT goldsteinhodaya syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT krasnermatan syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT barbiromichaelyefrat syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT gerberdoron syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT kazimirskygila syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT rogerslisa syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT brownstephan syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes
AT brodiechaya syst24propofolexertsantitumoreffectsingliomaandthetumormicroenvironmentvianoncodingrnasandsecretedexosomes